{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:06:29Z","timestamp":1793405189819,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-08669-w","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:16:44Z","timestamp":1752513404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["How to predict early mortality in patients with metastatic melanoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Qiusheng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengpai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaochen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"10151","key":"8669_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf, D. et al. Melanoma. Lancet (London England) 392 (10151), 971\u2013984 (2018).","journal-title":"Lancet (London England)"},{"issue":"8","key":"8669_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Reviews Clin. Oncol. 14 (8), 463\u2013482 (2017).","journal-title":"Nat. Reviews Clin. Oncol."},{"issue":"1","key":"8669_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","volume":"20","author":"K Namikawa","year":"2019","unstructured":"Namikawa, K. & Yamazaki, N. Targeted therapy and immunotherapy for melanoma in Japan. Curr. Treat. Options Oncol. 20 (1), 7 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"5","key":"8669_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2022. Cancer J. Clin. 72 (5), 409\u2013436 (2022).","journal-title":"Cancer J. Clin."},{"issue":"6","key":"8669_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.urolonc.2018.03.017","volume":"36","author":"S Caulfield","year":"2018","unstructured":"Caulfield, S., Menezes, G., Marignol, L. & Poole, C. Nomograms are key decision-making tools in prostate cancer radiation therapy. Urol. Oncol. 36 (6), 283\u2013292 (2018).","journal-title":"Urol. Oncol."},{"issue":"1","key":"8669_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00595-023-02695-9","volume":"54","author":"R Karita","year":"2024","unstructured":"Karita, R. et al. A simple nomogram for predicting occult lymph node metastasis of non-small cell lung cancer from preoperative computed tomography findings, including the volume-doubling time. Surg. Today. 54 (1), 31\u201340 (2024).","journal-title":"Surg. Today"},{"issue":"1","key":"8669_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eururo.2008.01.004","volume":"54","author":"SF Shariat","year":"2008","unstructured":"Shariat, S. F., Margulis, V., Lotan, Y., Montorsi, F. & Karakiewicz, P. I. Nomograms for bladder cancer. Eur. Urol. 54 (1), 41\u201353 (2008).","journal-title":"Eur. Urol."},{"issue":"7","key":"8669_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2340\/00015555-2944","volume":"98","author":"S Ribero","year":"2018","unstructured":"Ribero, S. et al. Effect of age on melanoma risk, prognosis and treatment response. Acta dermato-venereologica. 98 (7), 624\u2013629 (2018).","journal-title":"Acta dermato-venereologica"},{"issue":"4","key":"8669_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 15 (4), 436\u2013444 (2014).","journal-title":"Lancet Oncol."},{"issue":"5","key":"8669_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.smim.2012.04.008","volume":"24","author":"R Solana","year":"2012","unstructured":"Solana, R. et al. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin. Immunol. 24 (5), 331\u2013341 (2012).","journal-title":"Semin. Immunol."},{"issue":"20","key":"8669_CR11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined Vemurafenib and Cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371 (20), 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"8669_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R. et al. Encorafenib plus binimetinib versus Vemurafenib or Encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19 (5), 603\u2013615 (2018).","journal-title":"Lancet Oncol."},{"key":"8669_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2021.04.028","volume":"152","author":"H Gogas","year":"2021","unstructured":"Gogas, H. et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination Encorafenib plus binimetinib: results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur. J. cancer (Oxford England: 1990). 152, 116\u2013128 (2021).","journal-title":"Eur. J. cancer (Oxford England: 1990)"},{"issue":"36","key":"8669_CR14","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer, R. et al. COLUMBUS 5-Year update: A randomized, Open-Label, phase III trial of Encorafenib plus binimetinib versus Vemurafenib or Encorafenib in patients with BRAF V600-Mutant melanoma. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 40 (36), 4178\u20134188 (2022).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"8669_CR15","unstructured":"Crocetti, E. et al. Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. Eur. J. Cancer (Oxford, England) 51 (15), 2179\u20132190 (2015)."},{"key":"8669_CR16","doi-asserted-by":"crossref","unstructured":"Garbe, C. et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2014Update 2022. Eur. J. Cancer (Oxford, England) 170, 256\u2013284 (2022).","DOI":"10.1016\/j.ejca.2022.04.018"},{"issue":"8","key":"8669_CR17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.47102\/annals-acadmedsg.V39N8p634","volume":"39","author":"TC Chua","year":"2010","unstructured":"Chua, T. C., Saxena, A. & Morris, D. L. Surgical metastasectomy in AJCC stage IV M1c melanoma patients with Gastrointestinal and liver metastases. Ann. Acad. Med. Singapore. 39 (8), 634\u2013639 (2010).","journal-title":"Ann. Acad. Med. Singapore"},{"key":"8669_CR18","unstructured":"CADTH Health Technology Review. BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis: Health Technologies (Canadian Agency for Drugs and Technologies in Health, 2024)."},{"issue":"1","key":"8669_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 165 (1), 35\u201344 (2016).","journal-title":"Cell"},{"issue":"1","key":"8669_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2010.09.007","volume":"20","author":"PV Dickson","year":"2011","unstructured":"Dickson, P. V. & Gershenwald, J. E. Staging and prognosis of cutaneous melanoma. Surg. Oncol. Clin. N. Am. 20 (1), 1\u201317 (2011).","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"36","key":"8669_CR21","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 27 (36), 6199\u20136206 (2009).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"8669_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaad.2021.09.075","volume":"86","author":"L Skudalski","year":"2022","unstructured":"Skudalski, L., Waldman, R., Kerr, P. E. & Grant-Kels, J. M. Melanoma: an update on systemic therapies. J. Am. Acad. Dermatol. 86 (3), 515\u2013524 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"8669_CR23","doi-asserted-by":"publisher","first-page":"e13145","DOI":"10.1111\/dth.13145","volume":"33","author":"N Garz\u00f3n-Orjuela","year":"2020","unstructured":"Garz\u00f3n-Orjuela, N. et al. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced\/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis. Dermatol. Ther. 33 (2), e13145 (2020).","journal-title":"Dermatol. Ther."},{"issue":"10\u201312","key":"8669_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/15384047.2015.1095401","volume":"22","author":"T Hughes","year":"2021","unstructured":"Hughes, T., Klairmont, M., Sharfman, W. H. & Kaufman, H. L. Interleukin-2, ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biol. Ther. 22 (10\u201312), 513\u2013526 (2021).","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"8669_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.clindermatol.2012.08.016","volume":"31","author":"JJ Luke","year":"2013","unstructured":"Luke, J. J. & Schwartz, G. K. Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin. Dermatol. 31 (3), 290\u2013297 (2013).","journal-title":"Clin. Dermatol."},{"issue":"2","key":"8669_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21599","volume":"70","author":"RR Kudchadkar","year":"2020","unstructured":"Kudchadkar, R. R., Lowe, M. C., Khan, M. K. & McBrien, S. M. Metastatic melanoma. Cancer J. Clin. 70 (2), 78\u201385 (2020).","journal-title":"Cancer J. Clin."},{"issue":"3","key":"8669_CR27","doi-asserted-by":"publisher","first-page":"1903827","DOI":"10.1080\/21645515.2021.1903827","volume":"18","author":"L Tagliaferri","year":"2022","unstructured":"Tagliaferri, L. et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum. Vaccines Immunotherapeutics. 18 (3), 1903827 (2022).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"issue":"3","key":"8669_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2217\/fon.14.300","volume":"11","author":"P Gorayski","year":"2015","unstructured":"Gorayski, P., Burmeister, B. & Foote, M. Radiotherapy for cutaneous melanoma: current and future applications. Future Oncol. (London England). 11 (3), 525\u2013534 (2015).","journal-title":"Future Oncol. (London England)"},{"key":"8669_CR29","doi-asserted-by":"crossref","unstructured":"Li, A. T. et al. External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes. Eur. J. Cancer (Oxford, England 189, 112901 (2023).","DOI":"10.1016\/j.ejca.2023.04.017"},{"key":"8669_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fbioe.2020.00206","volume":"8","author":"Y Sheng","year":"2020","unstructured":"Sheng, Y. et al. Predicting the risk of melanoma metastasis using an immune risk score in the melanoma cohort. Front. Bioeng. Biotechnol. 8, 206 (2020).","journal-title":"Front. Bioeng. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08669-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:25:26Z","timestamp":1757237126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08669-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8669"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08669-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out by relevant guidelines and regulations. Data extraction and usage have been approved by the SEER Program. All the data can be found in the SEER dataset: .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25395"}}